The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer
Creators
- 1. Department of Medical Oncology, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai (China)
- 2. Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, BC (Canada)
- 3. Department of Nuclear Medicine, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai (China)
- 4. Department of Medical Oncology, Fudan University Shanghai Cancer Center Minhang Branch, Fudan University, Shanghai (China)
Description
Whether PET scan maximum standard uptake value (SUVmax) could differentiate luminal A from luminal B and help predict the survival of metastatic breast cancer (MBC) patients with luminal subtype is still unknown and need to be investigated. 305 MBC patients with luminal subtypes were screened with PET/CT. Eligible patients were prospectively followed up. In total, 134 patients were eligible for this study. SUVmax was significantly related to the number of metastatic sites and presence of visceral metastasis on univariate analysis. SUVmax could not effectively differentiate patients with luminal A from luminal B subtype. Although luminal subtype at diagnosis could predict the relapse-free interval, it could not predict progression-free survival (PFS) or overall survival (OS) after developing relapse. In contrast, SUVmax was predictive of both PFS and OS and this effect was maintained in multivariate COX regression model. SUVmax of MBC did not correlate with molecular subtypes of primary tumor. While molecular subtype may be a valuable prognostic factor at primary diagnosis of breast cancer, the SUVmax, rather than molecular subtype, does have a potential to predict independently in multivariate analysis for the PFS and OS in patients with metastatic disease of luminal subtype
Availability note (English)
Available from http://dx.doi.org/10.1186/1471-2407-13-42; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583732Additional details
Identifiers
Publishing Information
- Journal Title
- BMC cancer (Online)
- Journal Volume
- 13
- Journal Page Range
- p. 42
- ISSN
- 1471-2407
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 46111958
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; HORMONES; MAMMARY GLANDS; MULTIVARIATE ANALYSIS; NEOPLASMS; PATIENTS; PHENOBARBITAL; POSITRON COMPUTED TOMOGRAPHY; RECEPTORS; UPTAKE
- Descriptors DEC
- ANESTHETICS; ANTICONVULSANTS; AZINES; BARBITURATES; BODY; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DISEASES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; GLANDS; HETEROCYCLIC COMPOUNDS; HYPNOTICS AND SEDATIVES; MATHEMATICS; MEMBRANE PROTEINS; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; ORGANIC OXYGEN COMPOUNDS; ORGANS; PROTEINS; PYRIMIDINES; STATISTICS; TOMOGRAPHY
Optional Information
- Copyright
- Copyright (c)2013 Zhang et al.
- Notes
- PMCID: PMC3583732; PUBLISHER-ID: 1471-2407-13-42; PMID: 23368410; OAI: oai:pubmedcentral.nih.gov:3583732; licensee BioMed Central Ltd.